Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19239788 | 0.96 | ALDH1A1 (0.52) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL19239689 | 0.92 | ALDH1A1 (0.55) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL23471810 | 0.92 | ALDH1A1 (0.50) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL10345306 | 0.90 | NAMPT (0.52) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL10345059 | 0.90 | NAMPT (0.52) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL24818366 | 0.90 | NAMPT (0.52) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL10660707 | 0.90 | NAMPT (0.52) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL22851659 | 0.90 | ALDH1A1 (0.53) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL18768756 | 0.90 | ALDH1A1 (0.53) | ALDH1A1LMNAPKMCNR1HPGD | |
| SCHEMBL16689691 | 0.90 | ALDH1A1 (0.53) | ALDH1A1LMNAPKMCNR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263897-A1 | CONJUGATE OF GALNAC AND SAPONIN, THERAPEUTIC COMPOSITION COMPRISING SAID CONJUGATE AND A GALNAC-OLIGONUCLEOTIDE CONJUGATE | SAPREME TECHNOLOGIES B.V. (NL) | 2023-08-24 | — | — | US | disclosed |
| US-11690818-B2 | Drug containing liver targeting specific ligand and thyroid hormone receptor agonist | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11690818-B2 | Drug containing liver targeting specific ligand and thyroid hormone receptor agonist | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210277401-A1 | Compositions and Methods for Modulating PKK Expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-10883104-B2 | Compositions and methods for modulating apolipoprotein (a) expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10875884-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | ISIS PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10793862-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-9994855-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9957504-B2 | Compositions and methods for modulating apolipoprotein (a) expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957292-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9932580-B2 | Compositions and methods for modulating HBV expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170183661-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170166899-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170159055-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277401-A1 | Compositions and Methods for Modulating PKK Expression | GCKR, PKM, PKLR | ALDH1A1 4215/4885LMNA 492/4885PKM 2/4885 |
| US-11690818-B2 | Drug containing liver targeting specific ligand and thyroid hormone receptor agonist | THRA, THRB, TSHR | ALDH1A1 1539/4885LMNA 2082/4885PKM 2202/4885 |
| US-10875884-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | TEK, PLIN3, FABP3 | ALDH1A1 2808/4885LMNA 930/4885PKM 2077/4885 |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | ALDH1A1 2808/4885LMNA 930/4885PKM 2077/4885 |
| US-20230263897-A1 | CONJUGATE OF GALNAC AND SAPONIN, THERAPEUTIC COMPOSITION COMPRISING SAID CONJUGATE AND A GALNAC-OLIGONUCLEOTIDE CONJUGATE | ASGR1, GYS2, HCCS | ALDH1A1 3111/4885LMNA 1062/4885PKM 2316/4885 |
| US-10883104-B2 | Compositions and methods for modulating apolipoprotein (a) expression | APOB, APOL1, LDLR | ALDH1A1 1781/4885LMNA 158/4885PKM 2945/4885 |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | APOB, APOL1, LDLR | ALDH1A1 2605/4885LMNA 287/4885PKM 4126/4885 |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | ALDH1A1 1477/4885LMNA 3182/4885PKM 1817/4885 |
| US-20170145424-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | ALDH1A1 2760/4885LMNA 703/4885PKM 3095/4885 |
| US-20170355727-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, GALNT1, GALNT6 | ALDH1A1 974/4885LMNA 843/4885PKM 3913/4885 |
| US-10844379-B2 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | ALDH1A1 1877/4885LMNA 595/4885PKM 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.